| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Product revenue, net | 97,800 | 96,042 | 88,183 | 83,841 |
| Cost of goods sold | 4,263 | 7,165 | 5,028 | 6,684 |
| Research and development | 14,585 | 14,410 | 14,255 | 13,511 |
| Selling, general and administrative | 37,578 | 35,160 | 32,723 | 28,713 |
| Litigation settlement | 0 | 0 | - | 12,500 |
| Total operating expenses | 56,426 | 56,735 | 52,006 | 61,408 |
| Income from operations | 41,374 | 39,307 | 36,177 | 22,433 |
| Interest and other income, net | 6,593 | 7,468 | 7,420 | 7,336 |
| Income before income taxes | 47,967 | 46,775 | 43,597 | 29,769 |
| Income tax benefit (expense) | -31,398 | 8,442 | 7,864 | 2,589 |
| Net income | 79,365 | 38,333 | 35,733 | 27,180 |
| Unrealized gain on available-for-sale securities | 657 | -158 | 580 | 2,146 |
| Foreign currency translation | -714 | 925 | - | - |
| Comprehensive income | 79,308 | 39,100 | 36,313 | 29,326 |
| Basic (in dollars per share) | 2.74 | 1.33 | 1.24 | 0.95 |
| Basic (in shares) | 28,953,000 | 28,910,000 | 28,815,000 | 28,716,000 |
| Diluted (in dollars per share) | 2.66 | 1.29 | 1.2 | 0.91 |
| Diluted (in shares) | 29,833,000 | 29,749,000 | 29,871,000 | 29,902,000 |
Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS)